Table 4

Characteristics of patients in remission (n = 21)

Characteristic


Time to Remission (weeks)

Mean (SD)

21.1 (12.7)

Median

24

Range

4, 34


Time in Absolute Sustained Remission (weeks)a

Mean (SD)

22.5 (7.5)

Median

25

Range

6, 30


Dose at Remissionb

20 mg, n (%)

5 (23.8)

30 mg, n (%)

2 (9.5)

35 mg, n (%)

4 (19.0)

40 mg, n (%)

2 (9.5)

50 mg, n (%)

8 (38.1)


Dose at the 32-week visit (prior to tapering)

20 mg, n (%)

5 (23.8)

30 mg, n (%)

3 (14.3)

35 mg, n (%)

4 (19.0)

40 mg, n (%)

1 (4.8)

50 mg, n (%)

8 (38.1)


Dose whilst in remission, mgc

Mean (SD)

30.7 (11.0)

Median

30

Range

10, 50


a Dose at remission is taken as the dose at first achieving absolute sustained remission for patients achieving absolute sustained remission, and the dose at the 32-week visit for those patients not achieving absolute sustained remission.

b Time in absolute sustained remission is taken as the difference between the 34-week visit and the week of first achieving absolute sustained remission for patients achieving absolute sustained remission, and as 0 weeks for patients not achieving absolute sustained remission.

c The dose of all episodes of remission i.e. a MADRS score of ≤8

Wade et al. BMC Psychiatry 2011 11:42   doi:10.1186/1471-244X-11-42

Open Data